Virax gets green light in Africa
Friday, 08 August, 2008
Melbourne's Virax Holdings has received approval from the South African Medicines Control Council to begin early stage trials of its HIV therapeutic vaccine.
The trial will cost over $6 million and will be funded by a consortium of global and African mining companies, including BHP Billiton. The vaccine is aimed at people already infected by HIV.
The trial involves Virax's Co-X-Gene technology, which is designed to co-express genes inside the cell. Genes are delivered by a fowlpox virus vector to express specific antigens and cytokines.
VIR201 has been tested in two early stage trials in Australia, both successful in suppressing virus levels, and has an open IND through the US FDA for a phase II clinical trial.
The Co-X-Gene technology has been licensed to French company Transgene, which is conducting a Phase IIa trial for its therapeutic cancer vaccine TG4010 as an adjunct to chemotherapy in patients with advanced lung cancer.
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
Diabetes drug reduces knee arthritis pain in overweight patients
A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...
